AusBiotech Ltd. Release: Major Life Science Investor Event the Largest Yet
10/28/2013 9:05:04 AM
28 October 2013 -- Australia’s biggest biotech investment event in this part of the world to date, Australia Biotech Invest 2013, opens today in Melbourne. The two-day investment event has attracted 35 presenting companies and 300 investors from around the world, providing a platform for Australian life science companies to showcase their innovation for investment and partnerships.
Australia Biotech Invest 2013 will lift the profile of the Australian biotechnology industry and create access to greater funding sources for local companies to develop world-class science into therapies, diagnostics and medical devices.
International investors such as Apposite Capital, Orbimed Asia, Ecor1cap, Fenex Capital Management and Medimmune Ventures are attending. Big pharma representatives include companies such as Genentech, Astrazeneca, Novo Nordisk A/S, Eli Lilly, Sanofi, Pfizer and Merck.
Discussions will cover global biotech investment trends and opportunities, key challenges, strategic partnering for long-term success, how to access investment out of Greater China, and biotech financing and business models for future growth. Local analysts and brokers will be on panels discussing biotech performance and the growth outlook in Australia and New Zealand. The event also features one-on-one meetings and networking activities.
Victorian Minister for Technology, the Honourable Gordon Rich-Phillips MLC, will launch the investment event, along with the new Guide for Life Science Company Directors (the Guide).
An important component of a thriving life science industry is the quality of company governance, which in turn will support the development of the broader industry. The Guide aims to support and enhance the performance of boards of directors leading public and private life science companies. AusBiotech developed the Guide with the support of the Victorian Government in collaboration with industry. The Guide, endorsed by the Australian Institute of Company Directors, is a companion document to the Code of Best Practice for Reporting Life Sciences Companies, which was developed with the Australian Securities Exchange (ASX) to support high standards of communication and market disclosure to promote investor confidence.
This year’s Australia Biotech Invest, supported by the Victorian Government, ‘Connecting capital with innovation’. It is jointly organised by AusBiotech and Beacon Events, who have also partnered to deliver biotechnology investor meetings in Hong Kong. Biotech Invest events draw key decision makers from the investment community including venture capitalists, private equity firms and investment bankers, as well as from governments. The events merge market intelligence with investment opportunities and act as a guide to successful biotech investment.
Media enquiries: Lorraine Chiroiu, AusBiotech’s Communications Manager, E: firstname.lastname@example.org
M: +61 (0) 429 801 118
Further information: Hayley Laing, Investment Program Manager, AusBiotech, E: email@example.com
M: +61 (0) 0414 474 972
Australia Biotech Invest 2013 – Connecting capital with innovation
28 – 29 October 2013
Melbourne Convention Centre, Melbourne, Australia
Victorian Minister for Technology, the Honourable Gordon Rich-Phillips MLC will launch the event and the Guide from 9.00 am on Monday 28 October.
AusBiotech is Australia's biotechnology industry organisation working on behalf of over 3,000 members in the areas of human health, medical devices, food technology, agriculture, environmental and industrial biotechnology, for more than 25 years.
AusBiotech is dedicated to the development, growth and prosperity of the Australian biotechnology industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world.
Help employers find you! Check out all the jobs and post your resume.
comments powered by